Valuation: Atossa Therapeutics, Inc.

Market Cap 21.44M 18.74M 17.29M 15.94M 30.04M 2.06B 30.71M 207M 81.29M 1.01B 80.53M 78.76M 3.48B P/E 2026 *
-0.57x
P/E 2027 * -0.72x
Enterprise Value 21.44M 18.74M 17.29M 15.94M 30.04M 2.06B 30.71M 207M 81.29M 1.01B 80.53M 78.76M 3.48B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+4.18%
1 week+5.06%
Current month+29.02%
1 month+23.88%
3 months-57.29%
6 months-73.01%
Current year-71.86%
1 week 2.21
Extreme 2.21
2.5
1 month 1.7
Extreme 1.7
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
68.55
10 years 1.7
Extreme 1.7
806.76
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
12/5/26 Free

Director

10,000 0.1161%
12/5/26
Ensisheim Partners LLC
OtherCompany 0 0%
12/5/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+4.18%+5.06%-80.28%-85.44% 21.44M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.47%+0.53%+49.73%+78.00% 24.36B
Weighted average by Cap. -0.05%-0.18%+79.43%+123.30%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.68M -30.15M -27.79M -52.39M -3.6B -53.55M -360M -142M -1.76B -140M -137M -6.07B -39.31M -34.36M -31.7M -29.22M -55.08M -3.79B -56.3M -379M -149M -1.85B -148M -144M -6.38B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
17/07/26 US$2.490 +4.18% 47,873
16/07/26 US$2.390 -2.05% 68,960
15/07/26 US$2.440 +7.96% 97,154
14/07/26 US$2.260 -5.83% 157,797
13/07/26 US$2.400 +1.27% 177,603
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.490USD
Average target price
22.00USD
Spread / Average Target
+783.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock